BioLizard NV
Making the most of your scientific data
BioLizard is a leading multi-national, data analytics and data management consulting company supporting digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies in drug discovery, translational research, diagnostics and more. The company leverages computational and biological expertise in data analytics and AI, bioinformatics, software and IT architecture, data architecture and governance. BioLizard enables data-driven R&D, drug and biomarker discovery and development, empowering life science companies to make the most of their data and research investments.
About BioLizard NV:
| Area of work | Data analytics and data management consulting as well as software engineering and bioinformatics. |
| Founders and Financing | Wim van Criekinge, Gerben Menschaert and Jan Van den Berghe, privately financed. |
| Partners | BioLizard cooperates with leading stakeholders in the industry such as Illumina, Pierre Fabre Oncology, Tercen, Flanders.Bio and the Pistoia Alliance. |
| USPs | BioLizard accommodates a uniquely qualified team of 50+ experts, the “Lizards”, who bring together their expertise and abilities, covering data management, software engineering, bioinformatics and AI-driven data analytics. At the same time, their background in biology and computer sciences enables them to apply specialist understanding for each client’s data and needs to provide insight and tools, maximizing return on investment. |
| Services | BioLizard provides consulting and hands-on data science support at every stage from disease modelling through to drug development. The team enables consistent, scientific based rigorous interpretation of biomedical data and builds user-friendly interfaces, removing the need for client expertise in data analytics and IT. Applications support discovery and validation of drugs, biomarkers and diagnostics, validation of published results and MoA modelling to predict individual drug-patient interactions and to design study protocols. |
| Foundation/Employees | *2018 / 50 |
Contact:
| Address | BioLizard nv Foreestelaan 88 9000 Ghent, Belgium |
| contact@lizard.bio | |
| Web Address | https://lizard.bio/ |
| Social Media |
ARTIKEL ZU DIESEN SCHLAGWORTEN
- 23 Millionen Euro für Smart Reporting
- Can biopharma’s drug-focused R&D strategy remain profitable?
- Vorschau auf die analytica 2024
- „Eine Flut hebt alle Boote“
- Wie künstliche Intelligenz die Gesundheitsindustrie verändert
- Hey, it’s a Match!
- Navigating the AI Revolution - A Venture Capitalist‘s Journey in Transforming Healthcare
- Heading the digital transformation in the life sciences industry
- How to achieve investment readiness in the food industry?
- The potential of AI in drug discovery
- BioLizard startet neue KI-unterstützte Plattform „BioVerse“
- W&I-Policen zunehmend für kleinere Deals zugänglich
- Was Künstliche Intelligenz im M&A-Geschäft bringt
- BioNTech schließt Übernahme von InstaDeep ab
- KI für Gewebeproben: AIgnostics erhält Seed-Finanzierung
- Münchener inveox erhält weiteres Investment
- Predicting clinical trial success and improving R&D
- IGES erwirbt Mehrheit des britischen Medizintechnik-Beratungsunternehmens Device Access UK
- Molecular Health lizenziert prädiktives analytisches Produkt MH Predict an DATEN CAPITAL
- EVOTEC beteiligt sich an Finanzierungsrunde für AI-Wirkstoffforschungsunternehmen Exscientia